Eltrombopag in Elderly Acute Myelogenous Leukemia (AML)
Status:
Terminated
Trial end date:
2015-11-10
Target enrollment:
Participant gender:
Summary
This is a phase I/II open label study being conducted to evaluate the overall safety and
initial effectiveness of an investigational drug, Eltrombopag in patients who are 60 years of
age and older and who have Acute Myelogenous Leukemia (AML). Eltrombopag is an
investigational drug, which means it has not been approved by the U.S. Food and Drug
Administration (FDA) for use in this type of disease. Approximately 35 people will be
enrolled on this study at the University of Pennsylvania
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Abramson Cancer Center of the University of Pennsylvania